Search

Your search keyword '"Kurokawa, Yuka"' showing total 26 results
Start Over Author "Kurokawa, Yuka"
26 results on '"Kurokawa, Yuka"'

4. Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial

Author

Kurokawa, Yuka, Kaida, Yusuke, Hazama, Takuma, Nakayama, Yosuke, Otome, Takaomi, Shibata, Ryo, Ito, Sakuya, Kodama, Goh, Nakamura, Nao, Kambe, Takatoshi, Moriyama, Tomofumi, Nagata, Akiko, Minami, Aki, Ando, Ryotaro, Wada, Yoshifumi, Sugiyama, Miki, Usui, Michiaki, Chiba, Michio, Moriyama, Atsuo, Ohara, Atsuko, Miyazaki, Hiroshi, Kakuma, Tatsuyuki, and Fukami, Kei

Published
2020
Full Text
View/download PDF

10. Erratum to: Screening of Fabry disease in patients with chronic kidney disease in Japan

Author

Nagata, Akiko, primary, Nasu, Makoto, additional, Kaida, Yusuke, additional, Nakayama, Yosuke, additional, Kurokawa, Yuka, additional, Nakamura, Nao, additional, Shibata, Ryo, additional, Hazama, Takuma, additional, Tsukimura, Takahiro, additional, Togawa, Tadayasu, additional, Saito, Seiji, additional, Sakuraba, Hitoshi, additional, and Fukami, Kei, additional

Published
2021
Full Text
View/download PDF

11. Screening of Fabry disease in patients with chronic kidney disease in Japan

Author

Nagata, Akiko, primary, Nasu, Makoto, additional, Kaida, Yusuke, additional, Nakayama, Yosuke, additional, Kurokawa, Yuka, additional, Nakamura, Nao, additional, Shibata, Ryo, additional, Hazama, Takuma, additional, Tsukimura, Takahiro, additional, Togawa, Tadayasu, additional, Saito, Seiji, additional, Sakuraba, Hitoshi, additional, and Fukami, Kei, additional

Published
2021
Full Text
View/download PDF

12. Effects of Reducing L-Carnitine Supplementation on Carnitine Kinetics and Cardiac Function in Hemodialysis Patients: A Multicenter, Single-Blind, Placebo-Controlled, Randomized Clinical Trial

Author

Sugiyama, Miki, primary, Hazama, Takuma, additional, Nakano, Kaoru, additional, Urae, Kengo, additional, Moriyama, Tomofumi, additional, Ariyoshi, Takuya, additional, Kurokawa, Yuka, additional, Kodama, Goh, additional, Wada, Yoshifumi, additional, Yano, Junko, additional, Otsubo, Yoshihiko, additional, Iwatani, Ryuji, additional, Kinoshita, Yukie, additional, Kaida, Yusuke, additional, Nasu, Makoto, additional, Shibata, Ryo, additional, Tashiro, Kyoko, additional, and Fukami, Kei, additional

Published
2021
Full Text
View/download PDF

13. Additional file 1 of Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial

Author

Kurokawa, Yuka, Kaida, Yusuke, Hazama, Takuma, Nakayama, Yosuke, Takaomi Otome, Shibata, Ryo, Sakuya Ito, Kodama, Goh, Nakamura, Nao, Kambe, Takatoshi, Tomofumi Moriyama, Nagata, Akiko, Minami, Aki, Ando, Ryotaro, Wada, Yoshifumi, Sugiyama, Miki, Usui, Michiaki, Chiba, Michio, Moriyama, Atsuo, Ohara, Atsuko, Miyazaki, Hiroshi, Kakuma, Tatsuyuki, and Fukami, Kei

Abstract

Additional file 1: Supplementary Table S1

Published
2020
Full Text
View/download PDF

14. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations

Author

Moriyama, Tomofumi, primary, Nakayama, Yosuke, additional, Soejima, Mikiko, additional, Yokota, Yunosuke, additional, Ota, Kanji, additional, Ito, Sakuya, additional, Kodama, Goh, additional, Nakamura, Nao, additional, Kurokawa, Yuka, additional, Yano, Junko, additional, Ueda, Utako, additional, Takamiya, Yoshimi, additional, Kaida, Yusuke, additional, Hazama, Takuma, additional, Shibata, Ryo, additional, Koda, Yoshiro, additional, and Fukami, Kei, additional

Published
2020
Full Text
View/download PDF

15. l ‐carnitine supplementation vs cycle ergometer exercise for physical activity and muscle status in hemodialysis patients: A randomized clinical trial

Author

Yano, Junko, primary, Kaida, Yusuke, additional, Maeda, Takashi, additional, Hashida, Ryuki, additional, Tonan, Tatsuyuki, additional, Nagata, Shuji, additional, Hazama, Takuma, additional, Nakayama, Yosuke, additional, Ito, Sakuya, additional, Kurokawa, Yuka, additional, Otome, Takaomi, additional, Shibata, Ryo, additional, Tashiro, Kyoko, additional, Kakuma, Tatsuyuki, additional, Matsuse, Hiroo, additional, and Fukami, Kei, additional

Published
2020
Full Text
View/download PDF

17. Screening of Fabry disease in patients with chronic kidney disease in Japan.

Author

Nagata, Akiko, Nasu, Makoto, Kaida, Yusuke, Nakayama, Yosuke, Kurokawa, Yuka, Nakamura, Nao, Shibata, Ryo, Hazama, Takuma, Tsukimura, Takahiro, Togawa, Tadayasu, Saito, Seiji, Sakuraba, Hitoshi, and Fukami, Kei

Subjects
ANGIOKERATOMA corporis diffusum, CHRONIC kidney failure, CHRONICALLY ill, MEDICAL screening, AMINO acid residues, GLYCOGEN storage disease type II
Abstract

Background Fabry disease (FD), an X-linked lysosomal storage disorder caused by a deficiency in alfa-galactosidase A (α-Gal A) activity due to mutations in the GLA gene, has a prevalence of 0–1.69% in patients undergoing haemodialysis; however, its prevalence in patients with chronic kidney disease (CKD) Stages 1–5 is unknown. Methods Serum α-Gal A activity analysis and direct sequencing of GLA were used to screen for FD in 2122 male patients with CKD, including 1703 patients with CKD Stage 5D and 419 with CKD Stages 1–5. The correlation between serum α-Gal A activity and confounding factors in patients with CKD Stages 1–5 was evaluated. Results FD prevalence rates in patients with CKD Stage 5D and CKD Stages 1–5 were 0.06% (1/1703) and 0.48% (2/419), respectively. A patient with CKD Stage 5D exhibited a novel GLA mutation, p.Met208Arg, whereas two patients with CKD Stages 1–5 had c.370delG and p.Met296Ile. p. Met208Arg caused moderate structural changes in the molecular surface region near the substituted amino acid residue but did not affect the catalytic residues Asp170 and Asp231 in α-Gal A. Serum α-Gal A activity in patients with CKD Stages 1–5 was inversely correlated with age (P < 0.0001) but directly correlated with estimated glomerular filtration rate (P < 0.0001). Conclusions FD prevalence was much higher in male patients with CKD Stages 1–5 than in those with CKD Stage 5D. FD screening in patients with CKD Stages 1–5 may improve patient survival, decreasing the number of patients with CKD Stage 5D. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. l‐carnitine supplementation vs cycle ergometer exercise for physical activity and muscle status in hemodialysis patients: A randomized clinical trial.

Author

Yano, Junko, Kaida, Yusuke, Maeda, Takashi, Hashida, Ryuki, Tonan, Tatsuyuki, Nagata, Shuji, Hazama, Takuma, Nakayama, Yosuke, Ito, Sakuya, Kurokawa, Yuka, Otome, Takaomi, Shibata, Ryo, Tashiro, Kyoko, Kakuma, Tatsuyuki, Matsuse, Hiroo, and Fukami, Kei

Subjects
CARNITINE, THIGH, CLINICAL trials, HEMODIALYSIS patients, PHYSICAL activity, MAGNETIC resonance imaging
Abstract

Serum carnitine is decreased in hemodialysis patients, which induces muscle atrophy. Thus, we examined the different effects of l‐carnitine and exercise on exercise activity and muscle status in hemodialysis patients. Twenty patients were divided into l‐carnitine and cycle ergometer groups and were followed for 3 months. Muscle and fat mass, physical activities, and muscle status were evaluated by an impedance, physical function test, and magnetic resonance imaging, respectively. The l‐carnitine significantly increased muscle mass (P =.023) and thigh circumference (P =.027), decreased fat mass (P =.007), and shortened chair stand‐up time (P =.002) and 10‐m walk test (P =.037). The fat fraction was improved by the l‐carnitine (P =.047). Compared with the exercise group, l‐carnitine improved the changes in 10‐m walk test (P =.026), chair stand‐up time (P =.014), and thigh circumference (P =.022). Baseline fibroblast growth factor‐21 and myostatin levels predicted the l‐carnitine‐associated changes in exercise activities. l‐carnitine, rather than exercise, improved physical activity and muscle status in hemodialysis patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. FP595EFFECT OF SWITCHING FROM CINACALCET TO ETELCALCETIDE ON SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH HEMODIALYSIS; ESCORT TRIAL

Author

Kurokawa, Yuka, primary, kaida, Yusuke, additional, Yano, Junko, additional, Takamiya, Yoshimi, additional, Otome, Takaomi, additional, Sugiyama, Miki, additional, Kojima, Aki, additional, Kumabe, Yuri, additional, Ito, Sakuya, additional, Kodama, Goh, additional, Nakamura, Nao, additional, Moriyama, Tomofumi, additional, Minami, Aki, additional, Nagata, Akiko, additional, Nakayama, Yosuke, additional, Shibata, Ryo, additional, Hazama, Takuma, additional, and Fukami, Kei, additional

Published
2018
Full Text
View/download PDF

23. AGEs–RAGE overexpression in a patient with smoking-related idiopathic nodular glomerulosclerosis

Author

Nakamura, Nao, primary, Taguchi, Kensei, additional, Miyazono, Yoshihiro, additional, Uemura, Keiichiro, additional, Koike, Kiyomi, additional, Kurokawa, Yuka, additional, Nakayama, Yosuke, additional, Kaida, Yusuke, additional, Shibata, Ryo, additional, Tsuchimoto, Akihiro, additional, Asanuma, Katsuhiko, additional, and Fukami, Kei, additional

Published
2017
Full Text
View/download PDF

24. L-carnitine Supplementation Improves Self-rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis

Author

Tashiro, Kyoko, primary, Kaida, Yusuke, additional, Yamagishi, Sho-ichi, additional, Tanaka, Hideharu, additional, Yokoro, Miyuki, additional, Yano, Junko, additional, Sakai, Kazuko, additional, Kurokawa, Yuka, additional, Taguchi, Kensei, additional, Nakayama, Yosuke, additional, Inokuchi, Takahiro, additional, and Fukami, Kei, additional

Published
2017
Full Text
View/download PDF

26. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.

Author

Nakayama, Yosuke, Ueda, Kaoru, Yamagishi, Sho-Ichi, Sugiyama, Miki, Yoshida, Chika, Kurokawa, Yuka, Nakamura, Nao, Moriyama, Tomofumi, Kodama, Goh, Minezaki, Tomohisa, Ito, Sakuya, Nagata, Akiko, Taguchi, Kensei, Yano, Junko, Kaida, Yusuke, Shibatomi, Kazutaka, and Fukami, Kei

Subjects
POLYSTYRENE, BONE metabolism, HYPERKALEMIA, HYPERPARATHYROIDISM treatment, THERAPEUTICS, DISEASE risk factors
Abstract

Background: Hyperkalemia is prevalent in end-stage renal disease patients, being involved in life-threatening arrhythmias. Although polystyrene sulfonate (PS) is commonly used for the treatment of hyperkalemia, direct comparison of effects between calcium and sodium PS (CPS and SPS) on mineral and bone metabolism has not yet been studied.Methods: In a randomized and crossover design, 20 pre-dialysis patients with hyperkalemia (>5 mmol/l) received either oral CPS or SPS therapy for 4 weeks.Results: After 4-week treatments, there was no significant difference of changes in serum potassium (K) from the baseline (ΔK) between the two groups. However, SPS significantly decreased serum calcium (Ca) and magnesium (Mg) and increased intact parathyroid hormone (iPTH) values, whereas CPS reduced iPTH. ΔiPTH was inversely correlated with ΔCa and ΔMg (r = −0.53 and r = −0.50, respectively). Furthermore, sodium (Na) and atrial natriuretic peptide (ANP) levels were significantly elevated in patients with SPS, but not with CPS, whereas ΔNa and ΔANP were significantly correlated with each other in all the patients. We also found that ΔNa and Δ(Na to chloride ratio) were positively correlated with ΔHCO3−. In artificial colon fluid, CPS increased Ca and decreased Na. Furthermore, SPS greatly reduced K, Mg, and NH3.Conclusion: Compared with SPS, CPS may be safer for the treatment of hyperkalemia in pre-dialysis patients, because it did not induce hyperparathyroidism or volume overload. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results